• Je něco špatně v tomto záznamu ?

Léčba hypertenze snižuje riziko srdečního selhání a cévních mozkových příhod i u starších pacientů
[Treatment of hypertension in patients 80 years of age or older]

Beckett NS, Peters R, Fletcher AE, et al.

. 2008 ; 6 (2) : 21-22.

Jazyk čeština Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc07513767

Whether the treatment of patients with hypertension who are 80 years of age or older is beneficial is unclear. It has been suggested that antihypertensive therapy may reduce the risk of stroke, despite possibly increasing the risk of death. METHODS: We randomly assigned 3845 patients from Europe, China, Australasia, and Tunisia who were 80 years of age or older and had a sustained systolic blood pressure of 160 mm Hg or more to receive either the diuretic indapamide (sustained release, 1.5 mg) or matching placebo. The angiotensin-converting-enzyme inhibitor perindopril (2 or 4 mg), or matching placebo, was added if necessary to achieve the target blood pressure of 150/80 mm Hg. The primary end point was fatal or nonfatal stroke. RESULTS: The active-treatment group (1933 patients) and the placebo group (1912 patients) were well matched (mean age, 83.6 years; mean blood pressure while sitting, 173.0/90.8 mm Hg); 11.8% had a history of cardiovascular disease. Median follow-up was 1.8 years. At 2 years, the mean blood pressure while sitting was 15.0/6.1 mm Hg lower in the active-treatment group than in the placebo group. In an intention-to-treat analysis, active treatment was associated with a 30% reduction in the rate of fatal or nonfatal stroke (95% confidence interval [CI], -1 to 51; P=0.06), a 39% reduction in the rate of death from stroke (95% CI, 1 to 62; P=0.05), a 21% reduction in the rate of death from any cause (95% CI, 4 to 35; P=0.02), a 23% reduction in the rate of death from cardiovascular causes (95% CI, -1 to 40; P=0.06), and a 64% reduction in the rate of heart failure (95% CI, 42 to 78; P<0.001). Fewer serious adverse events were reported in the active-treatment group (358, vs. 448 in the placebo group; P=0.001). CONCLUSIONS: The results provide evidence that antihypertensive treatment with indapamide (sustained release), with or without perindopril, in persons 80 years of age or older is beneficial. (ClinicalTrials.gov number, NCT00122811 [ClinicalTrials.gov].). Copyright 2008 Massachusetts Medical Society.

Treatment of hypertension in patients 80 years of age or older

Recenze v:

Komentář [k článku Léčba hypertenze snižuje riziko srdečního selhání a cévních mozkových příhod i u starších pacientů].

000      
00000naa 2200000 a 4500
001      
bmc07513767
003      
CZ-PrNML
005      
20111210124719.0
008      
081211s2008 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Beckett NS, N. S.
245    10
$a Léčba hypertenze snižuje riziko srdečního selhání a cévních mozkových příhod i u starších pacientů / $c Beckett NS, Peters R, Fletcher AE, et al.
246    11
$a Treatment of hypertension in patients 80 years of age or older
314    __
$a Care of the Elderly, Division of Medicine, Imperial College, London
520    9_
$a Whether the treatment of patients with hypertension who are 80 years of age or older is beneficial is unclear. It has been suggested that antihypertensive therapy may reduce the risk of stroke, despite possibly increasing the risk of death. METHODS: We randomly assigned 3845 patients from Europe, China, Australasia, and Tunisia who were 80 years of age or older and had a sustained systolic blood pressure of 160 mm Hg or more to receive either the diuretic indapamide (sustained release, 1.5 mg) or matching placebo. The angiotensin-converting-enzyme inhibitor perindopril (2 or 4 mg), or matching placebo, was added if necessary to achieve the target blood pressure of 150/80 mm Hg. The primary end point was fatal or nonfatal stroke. RESULTS: The active-treatment group (1933 patients) and the placebo group (1912 patients) were well matched (mean age, 83.6 years; mean blood pressure while sitting, 173.0/90.8 mm Hg); 11.8% had a history of cardiovascular disease. Median follow-up was 1.8 years. At 2 years, the mean blood pressure while sitting was 15.0/6.1 mm Hg lower in the active-treatment group than in the placebo group. In an intention-to-treat analysis, active treatment was associated with a 30% reduction in the rate of fatal or nonfatal stroke (95% confidence interval [CI], -1 to 51; P=0.06), a 39% reduction in the rate of death from stroke (95% CI, 1 to 62; P=0.05), a 21% reduction in the rate of death from any cause (95% CI, 4 to 35; P=0.02), a 23% reduction in the rate of death from cardiovascular causes (95% CI, -1 to 40; P=0.06), and a 64% reduction in the rate of heart failure (95% CI, 42 to 78; P<0.001). Fewer serious adverse events were reported in the active-treatment group (358, vs. 448 in the placebo group; P=0.001). CONCLUSIONS: The results provide evidence that antihypertensive treatment with indapamide (sustained release), with or without perindopril, in persons 80 years of age or older is beneficial. (ClinicalTrials.gov number, NCT00122811 [ClinicalTrials.gov].). Copyright 2008 Massachusetts Medical Society.
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a inhibitory ACE $x škodlivé účinky $x terapeutické užití $7 D000806
650    _2
$a antihypertenziva $x škodlivé účinky $x terapeutické užití $7 D000959
650    _2
$a krevní tlak $x účinky záření $7 D001794
650    _2
$a kardiovaskulární nemoci $x epidemiologie $x prevence a kontrola $7 D002318
650    _2
$a diuretika $x škodlivé účinky $x terapeutické užití $7 D004232
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a hypertenze $x farmakoterapie $x mortalita $7 D006973
650    _2
$a indapamid $x škodlivé účinky $x terapeutické užití $7 D007190
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a perindopril $x škodlivé účinky $x terapeutické užití $7 D020913
650    _2
$a cévní mozková příhoda $x mortalita $x prevence a kontrola $7 D020521
700    1_
$a Peters, R.
700    1_
$a Fletcher, A. E.
773    0_
$w MED00012709 $t Postgraduální nefrologie $g Roč. 6, č. 2 (2008), s. 21-22 $x 1214-178X
787    18
$w bmc07513769 $i Recenze v: $t Komentář [k článku Léčba hypertenze snižuje riziko srdečního selhání a cévních mozkových příhod i u starších pacientů]
856    41
$u http://www.transplant.cz/vzdelavani/2008/08_02_04.pdf $y plný text volně přístupný
910    __
$a ABA008 $b B 2318 $c 893 $y 1
990    __
$a 20081211073950 $b ABA008
991    __
$a 20090106100351 $b ABA008
999    __
$a ok $b bmc $g 629364 $s 481817
BAS    __
$a 3
BMC    __
$a 2008 $b 6 $c 2 $d 21-22 $i 1214-178X $m Postgraduální nefrologie $x MED00012709
LZP    __
$a 2008-22/mkme

Najít záznam

Citační ukazatele

    Možnosti archivace